Please login to the form below

Not currently logged in
Email:
Password:

Medius Deal Watch

This page shows the latest Medius Deal Watch news and features for those working in and with pharma, biotech and healthcare.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    Deal Watch March 2017. Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up. ... Each month the Deal Watch team ploughs our merry way through the details of 600 plus deals to bring you the edited

  • Deal Watch February 2017 Deal Watch February 2017

    Deal Watch February 2017. Actelion, Johnson &Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up. ... The deal also includes a licence to AKB-5169 (formerly JNJ5169), an oral, preclinical stage compound for inflammatory bowel

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    On reviewing the data captured in its monthly Deal Watch reviews Medius said a significant downturn in deal activity was evident. ... This article was based on Medius' Annual Review of its Deal Watch service.

  • Deal Watch January 2017 Deal Watch January 2017

    Deal Watch January 2017. Actelion, Johnson &Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up. ... Deal Watch table spending its overseas dollars on the acquisition of Actelion for an all cash deal of $30bn (30 times price to

  • Deal Watch December 2016 Deal Watch December 2016

    Deal Watch December 2016. Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up. ... Behind the headlines of these early stage deals it is notable that four of these 13 out-licensing companies are frequent fliers in

More from intelligence
Approximately 28 fully matching, plus 23 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics